-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The Evolving Frontline Management of CLL: Are Triplets Better Than Doublets? How Will We Find Out?

Program: Education Program
Session: It's a Different World: CLL 2024
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, Combination therapy, CLL, Diseases, Therapy sequence, Treatment Considerations, Lymphoid Malignancies
Monday, December 9, 2024, 10:30 AM-11:45 AM

Jennifer A. Woyach, MD

Division of Hematology, The Ohio State University, Columbus, OH

Disclosures: Woyach: Merck: Consultancy; Schrodinger: Research Funding; Newave: Consultancy; Loxo Lilly: Consultancy; Janssen: Research Funding; Genentech, Inc.: Consultancy; AbbVie: Research Funding; AstraZeneca: Consultancy; BeiGene: Consultancy; Pharmacyclics: Consultancy, Research Funding; Morphosys: Research Funding.

OffLabel Disclosure:

See more of: It's a Different World: CLL 2024
See more of: Education Program
<< Previous Presentation | Next Presentation >>